The proposed bill amends Florida Statutes to enhance the regulation of xylazine, a controlled substance, by modifying section 893.03 to exempt FDA-approved xylazine drug products for specific uses, while clarifying that the manufacture, importation, distribution, prescribing, or sale of xylazine for human use is not exempt. It introduces new criminal penalties under section 893.13 for individuals involved in the sale, manufacture, delivery, or possession of xylazine with intent to sell, establishing a mandatory minimum term of imprisonment. Additionally, the bill creates a new offense under section 893.135 for trafficking in xylazine, with penalties and mandatory minimum terms of imprisonment and fines based on the quantity involved.

Furthermore, the bill expands the list of controlled substances to include various synthetic cannabinoids and substituted cathinones, detailing specific compounds and establishing criteria for their classification. It emphasizes that any material containing these substances will be classified as controlled unless exempted or FDA-approved. The bill also updates penalties for trafficking in illegal drugs, including xylazine, with specific mandatory minimum sentences and fines based on the quantity trafficked. The legislation is set to take effect on October 1, 2025, aiming to address the growing concerns regarding the misuse of xylazine and enhance public safety through stricter enforcement measures.

Statutes affected:
S 1360 Filed: 893.13, 893.135
S 1360 c1: 893.03, 893.135